Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Development of MAP4 Kinase Inhibitors as Motor Neuron-Protecting Agents.

Bos PH, Lowry ER, Costa J, Thams S, Garcia-Diaz A, Zask A, Wichterle H, Stockwell BR.

Cell Chem Biol. 2019 Dec 19;26(12):1703-1715.e37. doi: 10.1016/j.chembiol.2019.10.005. Epub 2019 Oct 31.

PMID:
31676236
2.

Biomimetic syntheses of racemic natural products.

Zask A, Ellestad G.

Chirality. 2018 Feb;30(2):157-164. doi: 10.1002/chir.22786. Epub 2017 Nov 15. Review.

PMID:
29139568
3.

Multivalent Small-Molecule Pan-RAS Inhibitors.

Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR.

Cell. 2017 Feb 23;168(5):878-889.e29. doi: 10.1016/j.cell.2017.02.006.

4.

Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.

Qian J, Chen Y, Meng T, Ma L, Meng L, Wang X, Yu T, Zask A, Shen J, Yu K.

Oncotarget. 2016 Oct 11;7(41):67071-67086. doi: 10.18632/oncotarget.11490.

5.

Applying the Ottawa Charter to inform health promotion programme design.

Fry D, Zask A.

Health Promot Int. 2017 Oct 1;32(5):901-912. doi: 10.1093/heapro/daw022.

PMID:
27099241
6.

Correlates of Gross Motor Competence in Children and Adolescents: A Systematic Review and Meta-Analysis.

Barnett LM, Lai SK, Veldman SLC, Hardy LL, Cliff DP, Morgan PJ, Zask A, Lubans DR, Shultz SP, Ridgers ND, Rush E, Brown HL, Okely AD.

Sports Med. 2016 Nov;46(11):1663-1688. doi: 10.1007/s40279-016-0495-z. Review.

7.

Recent Advances in Stereoselective Drug Targeting.

Zask A, Ellestad GA.

Chirality. 2015 Sep;27(9):589-97. doi: 10.1002/chir.22470. Epub 2015 Jun 11. Review.

PMID:
26096879
8.

Three-year follow-up of an early childhood intervention: what about physical activity and weight status?

Barnett LM, Zask A, Rose L, Hughes D, Adams J.

J Phys Act Health. 2015 Mar;12(3):319-21. doi: 10.1123/jpah.2013-0419. Epub 2014 May 6.

PMID:
24809753
9.

Integrating relationship- and research-based approaches in Australian health promotion practice.

Klinner C, Carter SM, Rychetnik L, Li V, Daley M, Zask A, Lloyd B.

Health Promot Int. 2015 Dec;30(4):891-902. doi: 10.1093/heapro/dau026. Epub 2014 May 6.

PMID:
24800758
10.

Face validity and reliability of a pictorial instrument for assessing fundamental movement skill perceived competence in young children.

Barnett LM, Ridgers ND, Zask A, Salmon J.

J Sci Med Sport. 2015 Jan;18(1):98-102. doi: 10.1016/j.jsams.2013.12.004. Epub 2014 Jan 2.

PMID:
24485803
11.

Smoking mull: a grounded theory model on the dynamics of combined tobacco and cannabis use among adult men.

Banbury A, Zask A, Carter SM, van Beurden E, Tokley R, Passey M, Copeland J.

Health Promot J Austr. 2013 Aug;24(2):143-50. doi: 10.1071/HE13037.

PMID:
24168742
12.

Biological stereoselectivity of atropisomeric natural products and drugs.

Zask A, Murphy J, Ellestad GA.

Chirality. 2013 May;25(5):265-74. doi: 10.1002/chir.22145. Review.

PMID:
23620262
13.

Synthesis of antioxidants for prevention of age-related macular degeneration.

Joshi D, Field J, Murphy J, Abdelrahim M, Schönherr H, Sparrow JR, Ellestad G, Nakanishi K, Zask A.

J Nat Prod. 2013 Mar 22;76(3):450-4. doi: 10.1021/np300769c. Epub 2013 Jan 24.

14.

Three year follow-up of an early childhood intervention: is movement skill sustained?

Zask A, Barnett LM, Rose L, Brooks LO, Molyneux M, Hughes D, Adams J, Salmon J.

Int J Behav Nutr Phys Act. 2012 Oct 22;9:127. doi: 10.1186/1479-5868-9-127.

15.

Prevalence and correlates of low fundamental movement skill competency in children.

Hardy LL, Reinten-Reynolds T, Espinel P, Zask A, Okely AD.

Pediatrics. 2012 Aug;130(2):e390-8. doi: 10.1542/peds.2012-0345. Epub 2012 Jul 23.

PMID:
22826575
16.

Tooty Fruity Vegie: an obesity prevention intervention evaluation in Australian preschools.

Zask A, Adams JK, Brooks LO, Hughes DF.

Health Promot J Austr. 2012 Apr;23(1):10-5.

PMID:
22730932
17.

Making sense in a complex landscape: how the Cynefin Framework from Complex Adaptive Systems Theory can inform health promotion practice.

Van Beurden EK, Kia AM, Zask A, Dietrich U, Rose L.

Health Promot Int. 2013 Mar;28(1):73-83. doi: 10.1093/heapro/dar089. Epub 2011 Nov 29.

PMID:
22128193
18.

Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.

Zask A, Verheijen JC, Richard DJ.

Expert Opin Ther Pat. 2011 Jul;21(7):1109-27. doi: 10.1517/13543776.2011.584871. Epub 2011 May 19. Review.

PMID:
21591993
19.

Reduction in staff smoking rates in North Coast Area Health Service, NSW, following the introduction of a smoke-free workplace policy.

Dart GS, van Beurden EK, Zask A, Lord C, Kia AM, Tokley R.

N S W Public Health Bull. 2010 Nov-Dec;21(11-12):263-6. doi: 10.1071/NB10036.

20.

Evidence, ethics, and values: a framework for health promotion.

Carter SM, Rychetnik L, Lloyd B, Kerridge IH, Baur L, Bauman A, Hooker C, Zask A.

Am J Public Health. 2011 Mar;101(3):465-72. doi: 10.2105/AJPH.2010.195545. Epub 2011 Jan 13.

21.

Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.

Richard DJ, Verheijen JC, Zask A.

Curr Opin Drug Discov Devel. 2010 Jul;13(4):428-40. Review.

PMID:
20597028
22.

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.

Zask A, Verheijen JC, Richard DJ, Kaplan J, Curran K, Toral-Barza L, Lucas J, Hollander I, Yu K.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2644-7. doi: 10.1016/j.bmcl.2010.02.045. Epub 2010 Feb 13.

PMID:
20227881
23.

Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha.

Richard DJ, Verheijen JC, Yu K, Zask A.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2654-7. doi: 10.1016/j.bmcl.2010.02.029. Epub 2010 Feb 11.

PMID:
20223664
24.

2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.

Verheijen JC, Richard DJ, Curran K, Kaplan J, Yu K, Zask A.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2648-53. doi: 10.1016/j.bmcl.2010.02.031. Epub 2010 Feb 11.

PMID:
20223663
25.

Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies.

Niu C, Ho DM, Williamson RT, Zask A, Ayral-Kaloustian S.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1535-8. doi: 10.1016/j.bmcl.2010.01.047. Epub 2010 Jan 20. Erratum in: Bioorg Med Chem Lett. 2012 Mar 1;22(5):2131. Williamson, Robert Thomas [added].

PMID:
20137930
26.

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.

Curran KJ, Verheijen JC, Kaplan J, Richard DJ, Toral-Barza L, Hollander I, Lucas J, Ayral-Kaloustian S, Yu K, Zask A.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1440-4. doi: 10.1016/j.bmcl.2009.12.086. Epub 2010 Jan 4.

PMID:
20089401
27.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

28.

Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

Kaplan J, Verheijen JC, Brooijmans N, Toral-Barza L, Hollander I, Yu K, Zask A.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):640-3. doi: 10.1016/j.bmcl.2009.11.050. Epub 2009 Dec 4.

PMID:
19963384
29.

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K.

J Med Chem. 2010 Jan 14;53(1):452-9. doi: 10.1021/jm901427g.

PMID:
19928864
30.

Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.

Zask A, Kaplan J, Verheijen JC, Richard DJ, Curran K, Brooijmans N, Bennett EM, Toral-Barza L, Hollander I, Ayral-Kaloustian S, Yu K.

J Med Chem. 2009 Dec 24;52(24):7942-5. doi: 10.1021/jm901415x.

PMID:
19916508
31.

Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.

Verheijen JC, Yu K, Toral-Barza L, Hollander I, Zask A.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):375-9. doi: 10.1016/j.bmcl.2009.10.075. Epub 2009 Oct 22.

PMID:
19897362
32.

Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.

Richard DJ, Verheijen JC, Curran K, Kaplan J, Toral-Barza L, Hollander I, Lucas J, Yu K, Zask A.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6830-5. doi: 10.1016/j.bmcl.2009.10.096. Epub 2009 Oct 25.

PMID:
19896845
33.

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

Verheijen JC, Richard DJ, Curran K, Kaplan J, Lefever M, Nowak P, Malwitz DJ, Brooijmans N, Toral-Barza L, Zhang WG, Lucas J, Hollander I, Ayral-Kaloustian S, Mansour TS, Yu K, Zask A.

J Med Chem. 2009 Dec 24;52(24):8010-24. doi: 10.1021/jm9013828.

PMID:
19894727
34.

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K.

J Med Chem. 2009 Nov 26;52(22):7081-9. doi: 10.1021/jm9012642.

PMID:
19848404
35.

Young driver education programs that build resilience have potential to reduce road crashes.

Senserrick T, Ivers R, Boufous S, Chen HY, Norton R, Stevenson M, van Beurden E, Zask A.

Pediatrics. 2009 Nov;124(5):1287-92. doi: 10.1542/peds.2009-0659. Epub 2009 Oct 5. Erratum in: Pediatrics. 2010 Feb;125(2):415.

PMID:
19805458
36.

Interrater objectivity for field-based fundamental motor skill assessment.

Barnett L, van Beurden E, Morgan PJ, Lincoln D, Zask A, Beard J.

Res Q Exerc Sport. 2009 Jun;80(2):363-8. No abstract available.

PMID:
19650402
37.

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, Malwitz DJ, Brooijmans N, Bard J, Svenson K, Lucas J, Toral-Barza L, Zhang WG, Hollander I, Gibbons JJ, Abraham RT, Ayral-Kaloustian S, Mansour TS, Yu K.

J Med Chem. 2009 Aug 27;52(16):5013-6. doi: 10.1021/jm900851f.

PMID:
19645448
38.
39.

Six year follow-up of students who participated in a school-based physical activity intervention: a longitudinal cohort study.

Barnett LM, van Beurden E, Morgan PJ, Brooks LO, Zask A, Beard JR.

Int J Behav Nutr Phys Act. 2009 Jul 29;6:48. doi: 10.1186/1479-5868-6-48.

40.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

41.

Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.

Zhang C, Lovering F, Behnke M, Zask A, Sandanayaka V, Sun L, Zhu Y, Xu W, Zhang Y, Levin JI.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3445-8. doi: 10.1016/j.bmcl.2009.05.020. Epub 2009 May 9.

PMID:
19464885
42.

Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.

Tsou HR, Liu X, Birnberg G, Kaplan J, Otteng M, Tran T, Kutterer K, Tang Z, Suayan R, Zask A, Ravi M, Bretz A, Grillo M, McGinnis JP, Rabindran SK, Ayral-Kaloustian S, Mansour TS.

J Med Chem. 2009 Apr 23;52(8):2289-310. doi: 10.1021/jm801026e.

PMID:
19317452
43.

The Mull Hypothesis: is cannabis use contributing to high tobacco use prevalence among young North Coast males?

van Beurden EK, Zask A, Passey M, Kia AM.

N S W Public Health Bull. 2008 Mar-Apr;19(3-4):72-4.

44.

Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.

Zask A, Kaplan J, Toral-Barza L, Hollander I, Young M, Tischler M, Gaydos C, Cinque M, Lucas J, Yu K.

J Med Chem. 2008 Mar 13;51(5):1319-23. doi: 10.1021/jm7012858. Epub 2008 Feb 13.

PMID:
18269228
45.

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.

Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A.

Cancer Biol Ther. 2008 Feb;7(2):307-15. Epub 2007 Nov 21.

PMID:
18059185
46.

Creating active playgrounds in primary schools.

Budgen P, Furber S, Gray E, Zask A.

Health Promot J Austr. 2007 Apr;18(1):77-9.

PMID:
17501716
47.

Is it worth the RRISK? Evaluation of the RRISK (Reduce Risk Increase Student Knowledge) program for adolescents in rural Australia.

Zask A, van Beurden E, Brooks LO, Dight R.

J Adolesc Health. 2006 May;38(5):495-503.

PMID:
16635759
48.

Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models.

Zhu T, Gu J, Yu K, Lucas J, Cai P, Tsao R, Gong Y, Li F, Chaudhary I, Desai P, Ruppen M, Fawzi M, Gibbons J, Ayral-Kaloustian S, Skotnicki J, Mansour T, Zask A.

J Med Chem. 2006 Feb 23;49(4):1373-8.

PMID:
16480272
49.

Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.

Zask A, Kaplan J, Musto S, Loganzo F.

J Am Chem Soc. 2005 Dec 21;127(50):17667-71.

PMID:
16351096
50.

Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin.

Ravi M, Zask A, Rush TS 3rd.

Biochemistry. 2005 Dec 6;44(48):15871-9.

PMID:
16313189

Supplemental Content

Support Center